Alnylam Pharmaceuticals, Inc. (ALNY) saw its loss widen to $112.93 million, or $1.32 a share for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $90.72 million, or $1.07 a share.

Revenue during the quarter surged 131.15 percent to $17.45 million from $7.55 million in the previous year period.

Operating loss for the quarter was $115.43 million, compared with an operating loss of $92.51 million in the previous year period.

"We continue to advance a broad pipeline of investigational RNAi therapeutics " including 8 programs in clinical development - across a wide range of disease indications with high unmet need. In the fourth quarter of 2016 and recent period, we reported positive clinical results with fitusiran for hemophilia, givosiran for porphyria, and ALN-CC5 for complement-mediated diseases. In addition, our partners at The Medicines Company, reported positive interim clinical data with inclisiran for hypercholesterolemia. On the other hand, we were disappointed to announce the discontinuation of our revusiran program due to safety findings, although our investigation to date indicates the findings are unique to this program and the clinical setting," said John Maraganore, Ph.D., chief executive officer of Alnylam.